Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group I) Patients This study is in follow-up


General Information

Age Group




Protocol Number


Background Information

The purpose of this study to evaluate the long-term safety and tolerability of inhaled LIQ861 (treprostinil) using a dry powder inhaler.

National Clinical Trial (NCT) identifier on NCT03399604

Offered At

Inova Heart and Vascular Institute
Advanced Lung Disease and Transplant Clinic
3300 Gallows Road, Falls Church, VA 22042

Principal Investigator

Oksana Shlobin, MD

Eligibility Information

  • Male or female patients =/> 18 years of age
  • Diagnosed with PAH belonging to Nice Clinical Classification Grp 1
  • NYHA Functional Class II-IV at Screening
  • Can complete a baseline 6MWD =/> 150m
  • FEV1 =/> 60% and FEV1/FVC ratio =/> 60% during the 6 month period before enrollment

Ineligibility Information

  • Diagnosed with PH in the Nice Classification Groups 2-5, or PAH Group 1 subgroups 1.4.3 (associated with portal hypertension) or 1.4.5 (associated with schistosomiasis)
  • Patient is currently taking oral prostacyclin analogues or agonists, including treprostinil and selexipag
  • Uncontrolled systemic hypertension (=/>160/100 mmHg)
  • Has had an atrial septostomy
  • Has had a pulmonary infarction within 2 weeks of screening
  • Pregnancy
  • Has had a stroke or transient ischemic attack within 6 months of screening
  • Severe hepatic or renal impairment